CP.TO 1.15VRT -18.06NVDA -7.33TSM -15.23JPM -6.1ZST.TO 0.01HSAV.TO -0.03HSUV.U.TO 0.03
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

27.72
-0.00 (0.00%)
as of Sep 14, 2026, 8:00:00 pm Market Open.
583 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconSep 14, 2026, 12:00 am

This summary was created by AI, based on 27 opinions in the last 12 months.

Pfizer Inc. (PFE) is perceived as a defensive stock with an attractive dividend yield around 6-7%, appealing to income-focused investors. However, many experts express concern about the company's growth potential following a reliance on COVID-19 vaccine revenues, which have receded. The consensus indicates that while PFE maintains a low valuation (PE around 8-10x), its growth is stagnant or uncertain due to impending patent expirations and the challenges associated with developing new blockbuster drugs. Moreover, there are worries that the ongoing focus on acquisitions may not lead to the anticipated revenue boosts. Despite these concerns, some analysts suggest PFE could still perform well for patient investors, especially as sector interest begins to build. Ultimately, the outlook remains cautious, with a preference noted for other stocks in the pharmaceutical sector that exhibit better growth trajectories.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
LLY
TRADE

Pfizer Inc(PFE)

May 25, 2004
Large, US pharmaceutical stocks typically do well in a rising interest rate environment.
Photo of Neil WickhamNeil WickhamUnlock Rating
$34.74

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

May 14, 2004
Photo of Gene HensslerGene Henssler
Owned
Unlock Rating
$35.53

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

May 13, 2004
A lot of international sales. Have one of the strongest pipelines. A great core holding.
Photo of Bob StodgellBob Stodgell
Owned
Unlock Rating
$35.40

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Apr 29, 2004
(Top Pick March 29/04. Up 2.5%.) Lots of upside potential.
Photo of Ross HealyRoss Healy
Owned
Unlock Rating
$35.57

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Apr 07, 2004
On his watch list. Have a very strong product offering. High quality management. Probably the best drug portfolio and retail pipeline.
Photo of Norman LevineNorman Levine
No
Unlock Rating
$35.67

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Apr 02, 2004
The inclusion in the DOW is significant and we'll give it an upward bias. One of the best pharmaceutical companies in the world. There is competition and drug pipelines are a little tougher. A little expensive.
Photo of Jonathen Wellum, B. Comm, B. ScJonathen Wellum, B. Comm, B. Sc
No
Unlock Rating
$36.00

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
WEAK BUY

Pfizer Inc(PFE)

Apr 01, 2004
Is going to be listed in the Dow on Monday which will have a positive impact for the short term. As a multiple in the low 20's. Has decent growth, but it's less than the multiple. Probably reasonably valued and any upside would make it overvalued.
Photo of Bruce Campbell (1)Bruce Campbell (1)Unlock Rating
$35.59

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Mar 29, 2004
Has reached about a 20-year valuation low. Relatively cheap.
Photo of Ross HealyRoss Healy
Owned
Unlock Rating
$35.02

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Mar 29, 2004
Have a great lineup of existing drug products and lots more in the pipeline. At about 18 X earnings. Cheap.
Photo of Rob CallanderRob Callander
Owned
Unlock Rating
$35.02

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Mar 19, 2004
Thinks it's going to grow earnings at 15% this year.
Photo of Paul O'NeilPaul O'Neil
Owned
Unlock Rating
$33.95

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Mar 09, 2004
(A top pick Dec 29/03. Up 7.2%.) Still likes. As far and away the best growth profile in pharmaceuticals. Growing the fastest even though it's the most expensive.
Photo of John Sinkins, CFAJohn Sinkins, CFA
Owned
Unlock Rating
$37.30

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Feb 19, 2004
Have a very good pipeline. Faces significant generic exposure for the next few years because of patent exposure. On his focus list and will probably stay there for some time.
Photo of Matt BaraschMatt Barasch
No
Unlock Rating
$37.28

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Feb 17, 2004
Feels it is going to move substantially higher in the next 12/18 months.
Photo of Gavin GrahamGavin Graham
Owned
Unlock Rating
$37.75

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
WAIT

Pfizer Inc(PFE)

Feb 10, 2004
Had a good run. Benefit you to wait. Buy when it is down a few dollars from current price.
Photo of Brad WillockBrad WillockUnlock Rating
$38.00

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jan 15, 2004
A great pharmaceutical company. Has a huge stable of drugs coming through.
Photo of Bob StodgellBob Stodgell
Owned
Unlock Rating
$34.82

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
Showing 736 to 750 of 890 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

BUG 4.44$44.48
GS -40.73$988.45
NFLX 2.92$80.32
DAL -0.11$79.8
DML.TO -0.16$4.03
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

CP.TO 1.15$124.99
VRT -18.06$239
NVDA -7.33$210.96
TSM -15.23$418.01
JPM -6.1$350.13

Popular Articles

Latest Sell Signals

AVGO -17.27$344.72
APP 10.28$334.24
XRE.TO 0.05$15.73
ORCL -5.49$144.79
ORCL -5.49$144.79

Most Recent Experts

Liz Young, Head of investment strategy at SoFi

Liz Young, Head of investment strategy at SoFi

SoFi

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Joe Terranova

Joe Terranova

Virtus Investment Partners

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like